Patents by Inventor Sandip Bibishan Bharate
Sandip Bibishan Bharate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041772Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.Type: ApplicationFiled: October 13, 2023Publication date: February 8, 2024Inventors: Sonali Sandip Bharate, Vikas Kumar, Mehak Gupta, Sumit Ghandhi, Ajay Kumar, Sandip Bibishan Bharate, Ram Vishwakarma
-
Patent number: 11878075Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.Type: GrantFiled: April 18, 2019Date of Patent: January 23, 2024Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Sonali Sandip Bharate, Vikas Kumar, Mehak Gupta, Sumit Gandhi, Ajay Kumar, Sandip Bibishan Bharate, Ram Vishwakarma
-
Patent number: 11446346Abstract: The present invention is related to a novel gastroretentive swellable oral dosage form for sustained or delayed release of bergenin, a active constituent of Bergenia ciliata extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract of bergenin-rich Bergenia ciliata with polymers has resulted in a sustained release of extract in the stomach over a period of 16-24 hrs. The said formulations are useful for the treatment of inflammatory diseases.Type: GrantFiled: September 11, 2018Date of Patent: September 20, 2022Assignee: Council of Scientific & Industrial ResearchInventors: Sonali Sandip Bharate, Rohit Singh, Mehak Gupta, Bikarma Singh, Anil Kumar Katare, Ajay Kumar, Sandip Bibishan Bharate, Ram Vishwakarma
-
Publication number: 20210308116Abstract: The present invention is related to the novel solid dispersion formulations of an anticancer compound of formula A and a process for preparing the same wherein the anticancer compound is formulated with hydrophilic polymer. The said formulation showed enhanced dissolution of the anticancer compound and improved in-vivo anticancer activity. The said formulations are useful for the treatment of various types of cancer.Type: ApplicationFiled: June 14, 2019Publication date: October 7, 2021Inventors: Sonali Sandip BHARATE, Vikas KUMAR, Mubashir Javed MINTOO, Dilip Manikrao MONDHE, Sandip Bibishan BHARATE, Ram VISHWAKARMA
-
Publication number: 20210284618Abstract: The present invention relates to the furanochalcone class of compounds of general formula A. The present invention particularly relates to the synthesis of furanochalcones and their CYP1A1, CYP1A2 and CYP1B1 inhibitory activity. In addition, the invention relates to the prevention or treatment of cancer caused by polyaromatic hydrocarbons (PAHs), 4-nitroquinoline-1-oxide, and N-nitroso-N-methylurea, heterocyclic amines, estrogen and 17?-estradiol, resulting from the inhibition of CYP1A1, CYP1A2 and CYP1B1 enzymes.Type: ApplicationFiled: August 11, 2017Publication date: September 16, 2021Inventors: Sandip Bibishan Bharate, Rajni Sharma, Prashant Joshi, Ram Vishwakarma, Bhabatosh Chaudhuri
-
Publication number: 20210137841Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.Type: ApplicationFiled: April 18, 2019Publication date: May 13, 2021Inventors: Sonali Sandip BHARATE, Vikas KUMAR, Mehak GUPTA, Sumit GANDHI, Ajay KUMAR, Sandip Bibishan BHARATE, Ram VISHWAKARMA
-
Publication number: 20200390843Abstract: The present invention is related to the novel oral dosage form for sustained release of crocin-1, a active constituent of Crocus sativus extract or fraction and a process for preparing the same wherein the extract is wet-granulated using excipients, biodegradable polymers and/or non-biodegradable polymers alone or in combination. The said formulations are useful for the treatment of chronic inflammatory diseases wherein NLRP3 inflammasome is involved.Type: ApplicationFiled: October 18, 2018Publication date: December 17, 2020Inventors: Sonali Sandip BHARATE, Vikas KUMAR, Rohit SINGH, Sarita RANI, Mehak GUPTA, Ajay KUMAR, Sandip Bibishan BHARATE, Ram VISHWAKARMA
-
Publication number: 20200316150Abstract: The present invention is related to a novel gastroretentive swellable oral dosage form for sustained or delayed release of bergenin, a active constituent of Bergenia ciliata extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract of bergenin-rich Bergenia ciliata with polymers has resulted in a sustained release of extract in the stomach over a period of 16-24 hrs. The said formulations are useful for the treatment of inflammatory diseases.Type: ApplicationFiled: September 11, 2018Publication date: October 8, 2020Inventors: Sonali Sandip Bharate, Rohit Singh, Mehak Gupta, Bikarma Singh, Anil Kumar Katare, Ajay Kumar, Sandip Bibishan Bharate, Ram Vishwakarma
-
Patent number: 10696688Abstract: The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3K? inhibition and their medicinal use as anticancer agents.Type: GrantFiled: November 21, 2016Date of Patent: June 30, 2020Assignee: Council of Scientific & Industrial ResearchInventors: Sandip Bibishan Bharate, Shashi Bhushan, Shabber Mohammed, Santosh Kumar Guru, Sonali Sandip Bharate, Vikas Kumar, Girish Mahajan, Mubashir Javed Mintoo, Dilip Manikrao Mondhe, Ram Vishwakarma
-
Publication number: 20200031845Abstract: The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3K? inhibition and their medicinal use as anticancer agents.Type: ApplicationFiled: November 21, 2016Publication date: January 30, 2020Inventors: Sandip Bibishan BHARATE, Shashi BHUSHAN, Shabber MOHAMMED, Santosh Kumar GURU, Sonali Sandip BHARATE, Vikas KUMAR, Girish MAHAJAN, Mubashir Javed MINTOO, Dilip Manikrao MONDHE, Ram VISHWAKARMA
-
Patent number: 10202374Abstract: The present invention relates to 6-aryl-4-phenylamino quinazolines of formula I wherein, R and R? are as herein described. The present invention particularly relates to synthesis and anticancer and phoshpoinositide-3-kinase-? (PI3K-?) inhibitory activity. In addition, the invention relates to methods of using compounds for treating or preventing various cancers such as pancreatic, prostate, breast and melanoma.Type: GrantFiled: February 16, 2015Date of Patent: February 12, 2019Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Ram Asrey Vishwakarma, Sandip Bibishan Bharate, Shashi Bhushan, Rammohan Rao Yadav, Santosh Kumar Guru, Prashant Joshi
-
Patent number: 10064840Abstract: A pharmaceutical composition for the treatment of multi-drug resistant infections includes an antimicrobial agent in combination the benzopyrano[3,4-b][1]benzopyran-12(6H)-one class of compound boeravinone B of Formula 1: The bio-efficacy of anti-infective drugs can be potentiated, when used in combination with boeravinone B. Boeravinone B can overcome the resistance or multi-drug resistance developed by bacteria against quinolone, mupirocin and macrolide class of anti-bacterial agents via inhibition of bacterial efflux pumps. Thus, the compositions can be used to treat or prevent drug-resistant bacterial diseases.Type: GrantFiled: October 21, 2015Date of Patent: September 4, 2018Assignee: Council of Scientific & Industrial ResearchInventors: Ram Vishwakarma, Ajay Kumar, Inshad Ali Khan, Sandip Bibishan Bharate, Prashant Joshi, Samsher Singh, Naresh Satti
-
Patent number: 9776989Abstract: The present invention relates to novel chromone alkaloid of formula 1 isolated from the plant Dysoxylum binectariferum. The compound 5,7-dihydroxy-6-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4H-chromen-4-one, is found to be a potential inhibitor of cell growth and proliferation and also inhibits production of pro-inflammatory cytokines. The formulations of this particular compound can be used for treatment of cancer and inflammation.Type: GrantFiled: March 31, 2014Date of Patent: October 3, 2017Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Ram Asrey Vishwakarma, Shreyans Kumar Jain, Sandip Bibishan Bharate, Abid Hamid Dar, Anamika Khajuria, Samdarshi Meena, Sunil Kumar Bhola, Asif Khurshid Qazi, Aashiq Hussain, Tabasum Sidi, Shaanker Ramanan Uma, Gudasalamani Ravikanth, Ramesh Vasudeva, Kumara Patel Mohana, Kotiganahalli Narayanagowda Ganeshaiah
-
Patent number: 9777014Abstract: The present invention relates to 2,3,4,4a-tetrahydro-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxypyrano[3,2-c]isochromen-6(10bH)-one analogs of the Formula I, wherein, R, R? and R? are as herein described. In addition, the invention relates to methods of using compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma and chronic obstructive pulmonary disorder.Type: GrantFiled: November 1, 2013Date of Patent: October 3, 2017Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Shreyans Kumar Jain, Tabasum Sidiq, Samdarshi Meena, Anamika Khajuria, Ram Asrey Vishwakarma, Sandip Bibishan Bharate
-
Publication number: 20170273939Abstract: A pharmaceutical composition for the treatment of multi-drug resistant infections includes an antimicrobial agent in combination the benzopyrano[3,4-b][1]benzopyran-12(6H)-one class of compound boeravinone B of Formula 1: The bio-efficacy of anti-infective drugs can be potentiated, when used in combination with boeravinone B. Boeravinone B can overcome the resistance or multi-drug resistance developed by bacteria against quinolone, mupirocin and macrolide class of anti-bacterial agents via inhibition of bacterial efflux pumps. Thus, the compositions can be used to treat or prevent drug-resistant bacterial diseases.Type: ApplicationFiled: October 21, 2015Publication date: September 28, 2017Applicant: Council of Scientific & Idustrial ResearchInventors: Ram VISHWAKARMA, Ajay KUMAR, Inshad Ali KHAN, Sandip Bibishan BHARATE, Prashant JOSHI, Samsher SINGH, Naresh SATTI
-
Publication number: 20170015662Abstract: The present invention relates to 6-aryl-4-phenylamino quinazolines of formula I wherein, R and R? are as herein described. The present invention particularly relates to synthesis and anticancer and phoshpoinositide-3-kinase-? (PI3K-?) inhibitory activity. In addition, the invention relates to methods of using compounds for treating or preventing various cancers such as pancreatic, prostate, breast and melanoma.Type: ApplicationFiled: February 16, 2015Publication date: January 19, 2017Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Ram Asrey Vishwakarma, Sandip Bibishan Bharate, Shashi Bhushan, Rammohan Rao Yadav, Santosh Kumar Guru, Prashant Joshi
-
Publication number: 20160122360Abstract: The present invention relates to 2,3,4,4a-tetrahydro-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxypyrano[3,2-c]isochromen-6(10bH)-one analogs of the Formula I, wherein, R, R? and R? are as herein described. In addition, the invention relates to methods of using compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma and chronic obstructive pulmonary disorder.Type: ApplicationFiled: November 1, 2013Publication date: May 5, 2016Applicant: Council of Scientific & Industrial ResearchInventors: Shreyans Kumar Jain, Tabasum Sidiq, Samdarshi Meena, Anamika Khajuria, Ram Asrey Vishwakarma, Sandip Bibishan Bharate
-
Publication number: 20160046611Abstract: The present invention relates to novel chromone alkaloid of formula 1 isolated from the plant Dysoxylum binectariferum. The compound 5,7-dihydroxy-6-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4H-chromen-4-one, is found to be a potential inhibitor of cell growth and proliferation and also inhibits production of pro-inflammatory cytokines. The formulations of this particular compound can be used for treatment of cancer and inflammation.Type: ApplicationFiled: March 31, 2014Publication date: February 18, 2016Inventors: Ram Asrey Vishwakarma, Shreyans Kumar Jain, Sandip Bibishan Bharate, Abid Hamid Dar, Anamika Khajuria, Samdarshi Meena, Sunil Kumar Bhola, Asif Khurshid Qazi, Aashiq Hussain, Tabasum Sidi, Shaanker Ramanan Uma, Gudasalamani Ravikanth, Ramesh Vasudeva, Kumara Patel Mohana, Kotiganahalli Narayanagowda Ganeshaiah